Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis
Lilian Varricchio, Camelia Iancu-Rubin, Bhaskar Upadhyaya, Maria Zingariello, Fabrizio Martelli, Paola Verachi, Cara Clementelli, Jean-Francois Denis, Adeeb H. Rahman, Gilles Tremblay, John Mascarenhas, Ruben A. Mesa, Maureen O’Connor-McCourt, Anna Rita Migliaccio, Ronald Hoffman
Lilian Varricchio, Camelia Iancu-Rubin, Bhaskar Upadhyaya, Maria Zingariello, Fabrizio Martelli, Paola Verachi, Cara Clementelli, Jean-Francois Denis, Adeeb H. Rahman, Gilles Tremblay, John Mascarenhas, Ruben A. Mesa, Maureen O’Connor-McCourt, Anna Rita Migliaccio, Ronald Hoffman
View: Text | PDF
Research Article Hematology

TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis

  • Text
  • PDF
Abstract

Myelofibrosis (MF) is a progressive chronic myeloproliferative neoplasm characterized by hyperactivation of JAK/STAT signaling and dysregulation of the transcription factor GATA1 in megakaryocytes (MKs). TGF-β plays a pivotal role in the pathobiology of MF by promoting BM fibrosis and collagen deposition and by enhancing the dormancy of normal hematopoietic stem cells (HSCs). In this study, we show that MF-MKs elaborated significantly greater levels of TGF-β1 than TGF-β2 and TGF-β3 to a varying degree, and we evaluated the ability of AVID200, a potent TGF-β1/TGF-β3 protein trap, to block the excessive TGF-β signaling. Treatment of human mesenchymal stromal cells with AVID200 significantly reduced their proliferation, decreased phosphorylation of SMAD2, and interfered with the ability of TGF-β1 to induce collagen expression. Moreover, treatment of MF mononuclear cells with AVID200 led to increased numbers of progenitor cells (PCs) with WT JAK2 rather than mutated JAK2V617F. This effect of AVID200 on MF PCs was attributed to its ability to block TGF-β1–induced p57Kip2 expression and SMAD2 activation, thereby allowing normal rather than MF PCs to preferentially proliferate and form hematopoietic colonies. To assess the in vivo effects of AVID200, Gata1lo mice, a murine model of MF, were treated with AVID200, resulting in the reduction in BM fibrosis and an increase in BM cellularity. AVID200 treatment also increased the frequency and numbers of murine progenitor cells as well as short-term and long-term HSCs. Collectively, these data provide the rationale for TGF-β1 blockade, with AVID200 as a therapeutic strategy for patients with MF.

Authors

Lilian Varricchio, Camelia Iancu-Rubin, Bhaskar Upadhyaya, Maria Zingariello, Fabrizio Martelli, Paola Verachi, Cara Clementelli, Jean-Francois Denis, Adeeb H. Rahman, Gilles Tremblay, John Mascarenhas, Ruben A. Mesa, Maureen O’Connor-McCourt, Anna Rita Migliaccio, Ronald Hoffman

×

Figure 1

AVID200 blocks the effect of exogenous TGF-β1/TGF-β3 as well TGF-β produced in an autocrine fashion.

Options: View larger image (or click on image) Download as PowerPoint
AVID200 blocks the effect of exogenous TGF-β1/TGF-β3 as well TGF-β produ...
(A) Absolute number of MKs (CD41/CD42) generated in cultures of MF and ND MNCs ± SEM (n = 5). The absolute number of MF-MKs was significantly greater than ND-MKs (**P < 0.01). (B) The levels of TGF-β1, TGF-β2, and TGF-β3 were quantified in media conditioned by ND and MF MNCs under MK differentiation conditions (day 11). Results are displayed as pg/mL of culture supernatant ± SEM (n = 5). Significantly greater levels of TGF-β1 were observed in the MF-MK CM (**P < 0.01, by ANOVA). (C) MNCs were cultured for 48 hours in the presence of recombinant TGF-β1, TGF-β2, or TGF-β3 (10 ng/mL) with and without AVID200 (50 nM). Western blot for pSMAD2 and total SMAD2/SMAD3 of the MNC cell lysate (n = 3). (D) Relative expression of pSMAD2 toward the corresponding SMAD2/SMAD3 band by Image Studio Lite 5.2 (**P < 0.01, by ANOVA). (E) Western blot for pSMAD2 and total SMAD2/SMAD3. GAPDH was used as an internal loading control for ND-MK and MF-MK cells. MK cultures were exposed on day 9 of differentiation to increasing concentrations of AVID200 for 48 hours. (F) Relative expression of pSMAD2 toward the corresponding SMAD2/SMAD3 band previously normalized toward GAPDH by Image Studio Lite 5.2. MF, myelofibrosis; MK, megakaryocyte; ND, normal donor; MNC, mononuclear cell; CM, conditioned media.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts